Company Overview
About Strand Therapeutics
Strand Therapeutics is developing programmable mRNA — modified messenger RNA that incorporates synthetic gene circuits (logic gates) that restrict therapeutic protein expression to the tumor microenvironment. The company raised $153 million in Series B financing in August 2025, bringing total funding to $256 million at a ~$571 million valuation. Strand presented Phase 1 data at ASCO 2025 showing a confirmed complete response for STX-001, and its STX-003 program — which uses intravenous delivery rather than intratumoral injection — is entering clinical testing in 2026.
Business Model & Competitive Advantage
Strand's "SignalLock" technology programs mRNA to sense tumor-specific biomarkers and only produce cytokines (immune-activating proteins) when those signals are detected. This tumor-conditional expression addresses the primary toxicity challenge of cytokine therapies: systemic cytokine production causes severe immune side effects. By restricting expression to tumor tissue, Strand's approach enables therapeutic cytokine levels at the tumor site while avoiding the off-tumor toxicities that have limited systemic cytokine therapy.
Competitive Landscape 2025–2026
STX-003's intravenous delivery is the field-advancing step: most current cancer mRNA programs require direct injection into the tumor (limiting treatment to accessible tumors). Systemic IV delivery that selectively activates in tumors throughout the body would enable treatment of metastatic disease — the patient population with the greatest unmet need.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Strand Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Strand Therapeutics has achieved $153M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Strand Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Strand Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Strand Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Strand Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →